HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Feb. 27, 2020 (HealthDay News) -- A new monitoring approach could help improve treatment of patients with tuberculosis (TB), researchers say.
TB is an infectious disease that primarily affects the lungs. Treatment involves multiple pills or injection drugs daily for at least six months. Successful treatment depends on the medications reaching pockets of TB bacteria in the lungs.
Researchers have developed a system using CT and PET scans to see whether a key medicine called rifampin is reaching those lung areas of TB bacteria.
"Up until now, the only way we've known that rifampin sometimes does not reach the bacteria inside cavities has been by examining portions of lungs surgically resected [removed] from patients for whom standard anti-TB therapy failed," said study lead author Dr. Alvaro Ordonez, a research associate in pediatrics at Johns Hopkins Medicine in Baltimore.
The noninvasive imaging technique is called dynamic 11C-rifampin PET/CT. A trial in 12 TB patients is described in a study published Feb. 17 in the journal Nature Medicine.
The researchers explained that the new technique used a tagged version of the drug, 11C-rifampin, allowing doctors to view its concentration in the lungs using PET scans. These scans revealed that the drug's presence was lowest in the TB-caused lung lesions and cavities.
"This is eye-opening since the lesions and cavities are the sites known to have the largest populations of bacteria in TB patients," Ordonez said in a Hopkins news release. "Therefore, rifampin is not getting where we need it most."
Using information from this technique, doctors could tailor the drug's dose to shorten treatment time.
"We now have evidence that imaging the lungs with PET and CT scans may help researchers and physicians better determine how much rifampin is reaching the bacteria over time, and then use the data to steer decisions for speedier and more effective TB-fighting measures such as higher doses of the drug," said senior author Dr. Sanjay Jain, professor of pediatrics, and radiology and radiological science at Hopkins School of Medicine.
Further human trials are needed to confirm the study's promising results, the researchers noted.
TB causes about 1.5 million deaths a year worldwide, according to the World Health Organization.
The American Lung Association has more on tuberculosis.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 26, 2022